Cyclacel Pharmaceuticals to conduct MDS research

Share On Facebook
share on Linkedin

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced plans for the clinical development of sapacitabine in a second potential indication for patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents.

© Mike Hodges

Key points:

– Cyclacel will conduct a Phase 2b randomized, controlled clinical trial (RCT) of a regimen of sapacitabine alternating with low dose chemotherapy versus an active control of low dose chemotherapy.
– Eligible patients will be aged 60 years or older with intermediate-2 or high-risk MDS who have failed prior hypomethylating agent therapy.
– Approximately 250 patients will be enrolled in the RCT.
– The primary endpoint will be overall survival.
– The RCT will be preceded by a feasibility survey and a lead-in stage.
– The MDS program was the subject of a recent Cyclacel fundraising.
– Sapacitabine, an oral nucleoside analogue, is being evaluated in the SEAMLESS Phase 3 clinical trial, as its first potential indication, in elderly patients with acute myeloid leukemia (AML). SEAMLESS is funded beyond data readout which is expected around the second half of 2015.

Spiro Rombotis, president and chief executive officer of Cyclacel, said, “Sapacitabine has shown promising overall survival in an ongoing Phase 2 clinical trial in MDS patients who have failed prior hypomethylating agent therapy.

“As we continue to enroll patients in the SEAMLESS pivotal trial of sapacitabine as first-line therapy in elderly patients with acute myeloid leukemia, with the goal of completing enrollment around the end of 2014, we are planning a controlled trial of sapacitabine in MDS after front-line failure. We are very much aware of the urgent, unmet medical need of patients with MDS and look forward to providing more details on our MDS program in coming months.”

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200806 07:59:05